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Broncboalveolar lavage using flexible fiberoptic bronchoscopy has emerged as a powerful investigative tool in
respiratory medicine. It has helped in better understanding of pathogenesis of various interstitial lung diseases
especially idiopathic pulmonary fibrosis and sarcoidosis. It has also been found useful in the diagnosis of various
infectious and non-infectious diseases of lung particularly in immunodeficient patients.Even though this technique
is used all over the world, it is still a research tool and more studies are required to exactly assess its value as a
diagnostic fool in clinical medicine. BAL is a safe procedure.
Introduction
Bronchoalveolar lavage (BAL) using
      a flexible fiberoptic bronchoscope has
emerged as an important investigative
tool in pulmonology during the last
decade1. BAL is a technique that allows
the recovery of both cellular and noncellular
components from the epithelial surface
of the lower respiratory tract and differs
from bronchial washings which refer to
the aspiration of either secretions or
small amounts of instilled saline from the
large airways2. The first bronchoalveolar
lavage was performed by Cantrell and
colleagues in 1973 in normal volunteers3.
Subsequently it has become an
acceptable procedure tosample the
contents of the lower respiratory tract4.
The analysis of cellular and molecular
components of the alveolar epithelial
lining fluid has helped to elucidate the
pathogenetic mechanisms and also to
 assess the activity of interstitial and other
lung diseasess. This review deals mainly
with the methods and the role of
bronchoalveolar lavage in the diagnosis
and management of various pulmonary
diseases.
Method of bronchoalveolar
lavage2,6 
Bronchcalveolar lavage is performed
with a flexible fiberoptic bronchoscope
(FOB) usually under local anesthesia2,6.
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It can also be performed in patients
with an oral or nasotracheal tube in
position by inserting the FOB through
the tube, provided its diameter is greater
than 6mm6. Patients can be pre-
 medicated with atropine (0.6mg IM). Local
anesthesia is accomplished by spraying
of the nasal, oral,pharyngeal and
laryngeal areas with 4% lidocaine. The
trachea, carina and bronchi can be
anesthetized by direct instillation of
1.5-2% lidocaine. BAL is a safe
procedure. Mild side-effects such as
coughing during lavage, fever and chills
some hours after lavage and transient
alveolar infiltration 24 hours after the
procedure can occur in a proportion of
subjects. Supplemental oxygen by
nasal prongs, ear oximetry and ECG-
monitoring are advised in patients with
s vere underlying disease or other
critical conditions.
In localized disease, the involved
segment is lavaged. However, in diffuse
lung disease, the middle lobe or lingula
has been most commonly used as
standard sites; occasionally a lateral or
anterior segment of a lower lobe is
also used. The bronchoscope is
wedged in fourth or fifth order bronchi,
taking care not to “overwedge” which
may result in less fluid recovery. BAL is
usually performed with buffered or
unbuffered, pyrogen-free saline (isotonic
0.9% NaCI) at room temperature or
warmed to body temperature (37°C). The
total volume instilled per site is 100 to
150ml, and it is usually instilled as five
20-ml aliquots or two or three 50-ml
aliquots. The maximum total voIume
used (all sites combined) is usually no
more than 300 ml7. After each aliquot
i  instilled, it is aspirated either by hand
suction into the syringe or by normal
clinical suction apparatus using negative
pressures of 25-100mm Hg into a
specimen trap. There is no special time‘
for lavage fluid to dwell in the lung before
it is removed. However, the patient can
be encouraged to take one or two
normal breaths before the fluid is
withdrawn. The recovery from first
aliquot is generally poor.Thereafter
the return from subsequent aliquots is
60 to 70% of the instilled volume in
normal subjects and the overall recovery
is above 50 to 60%. Recovery of fluid is
d creased in smokers and in most
patients with diseased lungs, especially
if airway obstruction exists. After
bronchoscopy, the subject should be
observed for 4 to 6 hours until the effects
of local anesthesia have worn away.
After measuring the recovered
volume, the bronchoalveolar lavage
fluid is strained through a sterile gauze
to remove the mucous particles. Total
cell count is done on a haemocytometer
in the unconcentrated lavage fluid and
expressed both as the absolute number
of cells recovered by lavage; or as
the concentration of cells per ml of
recovered lavage fluid.Cell viability
can be performed by the Trypan blue
exclusion test. Total cell counts can
also be done after centrifugation.
However, this may result in loss of
cells. Differential cell count can be
d ne from millipore filter preparations,
which can be stained with a modified
hematoxylin- eosin method or with a
PAP technique. Differential ceil counts
can also be made from a cytocentrifuged
cell preparation stained with Wright-
51
Giemsa. However, this method
underestimates the percentage of
lymphocytes, especially if their proportion
is increased. The differential counts
are made by viewing with a light
microscope, employing objectives of
x40 x 100. At least 300-500 cells
should be counted. The cells recovered
from a normal non-smoking individual
are alveolar macrophages, lymphocytes,
neutrophils, eosinophils, mast cells and
  occasionally plasma cells. A high
percentage of epithelial cells (>5%)
is indicative of contamination with
bronchial inflammatory cells. Special
 immunofluorescent and
immunocytochemical techniques using  
monoclonal antibodies directed against
antigens present on the ceil surface of
lymphocytes and/or monocytes/
macrophages can be applied for better
characterization of the nature of the
cells recovered by the BAL.
The saline used for lavage
significantly dilutes the epithelial lining
fluid. Therefore, the soluble components
in BAL cannot be quantitated because
a completely reliable denominator or
reference substance is not yet available.
Even though albumin, potassium,
methylene blue and urea were tried
previously, no ideal. denominator or
method of calculation exists to quantitate
the dilution factor.                                  
BAL in healthy volunteers
Cellular and acellular constituents
in bronchoalveolar lavage fluid (BALF)
in non-smoking adults 8 are given in
Table 1. In smokers, the cell yield is 3
to 4 times greater. An increased number
of alveolar macrophages is recovered
from smokers and there may also be a
 slight increase(1-4%) in neutrophils. In
healthy smokers, the proportion of BAL
T-helper cells was lower, T-suppressor
cells higher and therefore, the helper -
suppressor ratio is lower than that in
non-smokers. BALF IgG was greater in
smokers than in never-smokers9.
diagnostic in some of the infectious
and non-infectious pulmonary diseases.
I  some others BAL findings may
contribute to the diagnosis, although they
are not diagnostic.
(a) Diseases in which BAL findings
are diagnostic
(i) Infectious diseases
In immunodeficient patients (eg.
patients receiving immunosuppressive
drugs and with advanced human
immunodeficient virus infection) with
pulmonary infiltrates suggesting lower
respiratory tract infection, BAL is a safe
procedure for making definitive aetiologic
diagnosis. In patients with HIV disease
and suspected Pneumocystis carinii
pneumonia, an induced sputum
examination should precedeBAL.
The isolat ion of pathogenic
microorganisms in lavage fluid can be
considered diagnostic only if the isolated
organism is not known to colonize the
respiratory tract. BAL also can be
useful in immunocompetent patients
especially with nosocomial pneumonia.
BAL fluid should be analyzed for
bacterial, fungal, opportunisticand
viral infections. Lavage differential cell
determination shows a lymphocytic
alveolitis in patients with HIV
infection. Infectious diseases that can
be diagnosed by isolation of
microorganisms from BAL fluid are shown
in Table 2.
(ii) Non-infectious disease
Even though the major contribution
of BAL was in understanding the
pathogenesis of lung injury, repair
and fibrosis especially in interstitial lung
disease, BAL findings are diagnostic
in a few of the followingnon-
infectious respiratory disorders (Table 2).
(a) Alveolar proteinosis
BAL fluid in alveolar proteinosis is
Table 1
Cel lu lar  and soluble const i tuents in BAL f lu id in
n o n - s m o k i n g  a d u l t s
Cel l s
           Total    
Macrophages %
   Lymphocytes %
T cells
Helper (CDA)
Suppressor (CDA)
B cells
Neutrophils %
Eosinophils %
Basophils %
Soluble factors
IgG, IgA    
IgM
C4, C3, factor B
C5
Mean ± SD)
    10 to 15 x106 cells/dl of BAL fluid.
84±1     
11 ±1 
6 2 ± 2  
46±3
25±2
5 ± 2
<1
<1
< 1
+
-
+
opaque and/or milky in appearance.
Microscopic evaluation reveals large
acellular eosinophilic bodies against a
background of small eosinophilic
granules and amorphous debris. On
combined Alcian blue - periodic acid-
schiff (PAS) stain, there is predominant
PAS staining of the proteinaceous material
with a lack of significant Alcian blue
staining. Small lamellar bodies of wavy
or regular periodicity, tubularmyelin
structures and myelin-like
multilamellated structures with electron
dense central region are characteristic
findings in electron microscopy.
carcinoma and lymphatic spread of
metastatic cancer. The diagnostic yield
had varied from 14 - 69% in various studies.
A number of tumor markers have been
studied, but none had proved to be
iagnostic.
Non-infectious diseases in
which BAL may be helpful in
diagnosis       
(i) Pulmonary haemorrhage
BAL fluid may be either bloody or
(b) Histiocytosis X (Langerhan’s
cell granulomatosis)  
Total 2 counts are increased in
BALF and 90% of the patients with
Langerhans  cell granulomatosis (LCG)
are smokers The differential cell count
reveals a high percentage of alveolar
macrophages, and a slight increase
of neutrophils and eosinophils. The
diagnostic feature is the demonstration
of Langerhans’ cells. These cells
contain characteristic pentalaminar plate-
like cytoplasmic organelles and
cytoplasmic inclusions variously referred
to as Langerhans’ granules, Birbeck’s
granules or histiocytosis X bodies which
can be demonstrated by electron
microscopy. Langerhans’ cells also
express CD a(T6) surface antigen. BAL    
1.
2.
3.
4.
5.
6.
7.
8.
9.
samples can be diagnostic if there are
greater than 5% of cells that react with
OKT6 antibody.
(c) Pulmonary malignancies
Bronchoalveolar lavage of affected
orange - pink in colour in patients with
pulmonary haemorrhage (PH) and
haemosiderosis. The total cellular count
and alveolar macrophages are increased
in PH. Presence of haemosiderosis laden
alveolar macrophages may aid in
diagnosis. Free red blood cells and red
blood ceils in macrophages can also be
observed in patients with PH.
(ii) Eosinophilic lung disease
Eosinophilic infiltrates in the lung can
Table 2
Infectious diseases in which isolation from BALF is
d iagnos t i c
Pneumocystis carinii
Toxoplasma gondii
Stronglyoides
Legionella
Histoplasma
Mycobacterium tuberculosis
Mycoplasma
Influenza
Respiratory syncytial virus
Non-infectious diseases in which analysis of BALF
is  diagnostic                                                               
1.    Alveolar proteinosis                                          
2. Langerhans’ cell granulomatosis (Histocytosis X).
3. Pulmonary malignancies
segments may permit a cytological
diagnosis of cancer. Bronchial and Non- infect ious diseases in which BALF f inding may
alveolar specimens can be processed in
any one of the following procedures: 1.
smears,   cytocentrifuge preparations,        2.
membrane filter preparations and cell
pellets embedded in paraffin. Processed 3.
samples canI be stained with 4.
Papanicolaou, Wright-Giemsa or 5.
haematoxylin-eosin stains.
be helpful  in  the diagnosis
Pulmonary haemorrhage
6.
Special stains using monoclonal
antibodies for tumor markers can also
Eosinophilic lung diseases
Occupational lung diseases (berylliosis, asbestosis)                   
Hypersensitivity pneumonitis
Idiopathic pulmonary fibrosis
Sarcoidosis
be employed.The diagnostic yield of(Modified from American Thoracic Society Statement, Am Rev Respir Dis 1990; ,142:
BAL is higher for bronchoalveolar cell    481-486)
occur in a variety of disorders such as
allergic broncho-pulmonary aspergillosis,
tropical eosinophilia and eosinophilic
pneumonia. Since eosinophils are not
seen in lavage fluid of normal controls,
any increase in eosinophils in BALF
suggests a pathologic process.The
highest eosinophil counts are usually
present in tropical eosinophilia and
eosinophilic pneumonia. A 5-10 fold
increase in total cells with a very high
eosinophil count in BALF in our country
may suggest tropical eosinophilia 10,11.
(iii) Occupational lung diseases
Berylliosis and asbestosis are
  two occupational lung diseases in
which BAL may be helpful in the
diagnosis. Berylliosis is a granulomatous
lung disease that is clinically and
histologically similar to sarcoidosis, but
the inciting antigen is known in berylliosis.
BALF shows macrophage-lymphocyte
alveolitis and most of the lymphocytes
are helper T calls. Proliferative response
of broncho-alveolar lymphocytes
especially CD4 + T cell subset to
beryllium salts can be utilized as a
diagnostic test. BAL in asbestosis is
characterized by several fold increases
in the numbers of alveolar macrophages
and by mild-to-moderate increases in
neutrophils and lymphocytes. There is a
good correlation between asbestos bodies
in BALF and in lung parenchyma. One
asbestos body per mil. of lavage fluid is
shown to be associated with more than
1000 asbestos bodies per gram of dried
lung parenchyma.
(iv) Hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP),
also known as extrinsic allergic alveolitis,
is an interstitial lung disease sociated
with repeated exposure to a wide range
of inhaled organic dusts and related
occupational allergens. BAL studies
reveal an increase in the proportion and
number of lymphocytes and majority of
lymphocytes* are CD8+ lymphocytes
resulting in a low CD4/CD8 ratio. The
presence of BAL lymphocytes
characterised by CD3+/CD8+/CD56+
CD57-/CD16- phenotype is highly
suggestive of Hp.
(v) Idiopathic pulmonary fibrosis
Alveolitis of activeidiopathic
pulmonary fibrosis (IPF) is characterized
by three to four fold increase intotal
numbers of lung effector cells and the
cells comprising alveolitis are mainly
alveolar macrophages andneutrophils
with smaller numbers oflymphocytes
and eosinophils. The combination of
increased neutrophils and eosinophils
occur in about two-thirds of patients with
IPF. Patients with lavage lymphocytosis
represent an earlier cellular stage in
inflammatory process of IPF and
improves with corticosteroids. However,
lavage eosinophilia is associated with
advanced IPF and is unresponsive to
treatment and lavage neutrophils do
not reflect response to treatment.
(vi) The alveolitis in sarcoidosis
 characterized by an increase in the
number of T-lymphocytesand
macrophages in the alveolar structures.
T-lymphocytes are mainly of helper/
induced type, resulting in an elevation of
helper to suppressor T-cell ratio.In
n appropriate clinical setting, BALF
T-cell lymphocytosis and CD4 : CD8 ratio
more than 3.5 can be consistent witha
diagnosis of sarcoidosis. More than
20% 01*/07* macrophages in lavage
fluid may also be helpful in the diagnosis
if combined with other parameters. An
increase in mast cells in BALF may
suggest initiation of fibrosis and thus is a
prognostic sign.
2. Therapeutic applications5
Whole lung lavage (WLL) has been
found to be useful in the treatment of
alveolarproteinosis. Mucus plugs can
be removed in patients with status
asthmaticus through a bronchosccpe after
the instillation of saline or acetylcysteine.
But, this procedure is associated with a
high risk benefit ratio. WLL has been
used to remove the irritating dust in the
acute form of silicosis in order to
prevent irreversible damage. WLL has
also been proposed in the treatment of
alveolar microlithiasis and exogenous
lipoidisis.
understanding the pathogenesis of various
interstitial lung diseases and has been
found to be useful in the dianogsis of
certain pulmonary disorders, it is still a
research tool and further studies are
required before it can be recommended
for general clinical use.
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